bexsero
gsk vaccines s.r.l. - outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant neisseria meningitidis group b fhbp fusion protein, recombinant neisseria meningitidis group b nada protein, recombinant neisseria meningitidis group b nhba fusion protein - meningitis, meningococcal - meningococcal vaccines - active immunisation against invasive disease caused by neisseria meningitidis serogroup-b strains.,
menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.
bexsero
glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - suspension for injection - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine - bexsero is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by neisseria meningitidis group b.
menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen
neisvac-c, 0.5 ml. suspension for injection in pre-filled syringe. meningococcal group c polysaccharide conjugate vaccine adsorbed
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - neisseria meningitidis, polysaccharide group, tetanus toxoid - suspension for injection - neisseria meningitidis polysaccharide group c tetanus toxoid - vaccines
bexsero vaccine suspension for injection 0.5ml pre-filled syringes
glaxosmithkline uk ltd - outer membrane vesicles (omv) from neisseria meningitidis group b containing the pora p1.4; neisseria meningitidis group b nhba fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b fhbp fusion protein - suspension for injection
trumenba (meningococcal group b vaccine) suspension for injection pre-filled syringe
pfizer australia pty ltd - neisseria meningitidis serogroup b recombinant lipidated- factor h binding protein subfamily a, quantity: 60 microgram; neisseria meningitidis serogroup b recombinant lipidated- factor h binding protein subfamily b, quantity: 60 microgram - injection, suspension - excipient ingredients: water for injections; aluminium phosphate; histidine; sodium chloride; polysorbate 80 - trumenba is indicated in individuals 10 years and older for active immunisation to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.
menveo
gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,
neisvac-c 0.5 ml suspension for injection in pre-filled syringe. meningococcal group c polysaccharide conjugate vaccine adsorbed
pfizer healthcare ireland - neisseria meningitidis c; tetanus toxoid - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - meningococcal vaccines - meningococcal vaccine - it is indicated for active immunisation in children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.
menveo meningococcal (groups a, c, w-135 and y) oligosaccharide crm197 conjugate vaccine
glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.